Evidence map›Paper›PMID 34395257›Full record

ArticleFrontiers in oncology2021

A First-In-Class, Humanized Antibody Targeting Alternatively Spliced Tissue Factor: Preclinical Evaluation in an Orthotopic Model of Pancreatic Ductal Adenocarcinoma.

Clayton S Lewis, Aniruddha Karve, Kateryna Matiash, Timothy Stone, Jingxing Li, Jordon K Wang, Henri H Versteeg, Bruce J Aronow, Syed A Ahmad, Pankaj B Desai and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Clayton S LewisDivision of Hematology/Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Aniruddha KarveDivision of Pharmaceutical Sciences, University of Cincinnati College of Pharmacy, Cincinnati, OH, United States.
Kateryna MatiashDivision of Hematology/Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Timothy StoneDepartment of Environmental Health, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Jingxing LiTechnology Development, LakePharma, Inc., Belmont, CA, United States.
Jordon K WangTechnology Development, LakePharma, Inc., Belmont, CA, United States.
Henri H VersteegEinthoven Laboratory for Experimental Vascular Medicine, Department of Internal Medicine, Leiden University Medical Center, Leiden, Netherlands.
Bruce J AronowDepartment of Biomedical Informatics, Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, United States.
Syed A AhmadDivision of Surgical Oncology, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Pankaj B DesaiDivision of Pharmaceutical Sciences, University of Cincinnati College of Pharmacy, Cincinnati, OH, United States.
Vladimir Y BogdanovDivision of Hematology/Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
University of Cincinnati Medical Center · USLakePharma (United States) · USChildren's Hospital & Medical Center · USLeiden University Medical Center · NL

Funding

Stem Cell/Organoid and Genome Editing CoreP30DK078392 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI Alexander Miethke · 2007 to 2026
$24.4M
Post-Graduate Hematology/Oncology Translational (PG-HOT) Training ProgramT32CA236764 · NCI · UNIVERSITY OF CINCINNATI · PI QI, XIAOYANG, SCAGLIONI, PIER PAOLO · 2019 to 2023
$2.1M
Alternatively Spliced Tissue Factor and Pathobiology of Pancreatic CancerR01CA190717 · NCI · UNIVERSITY OF CINCINNATI · PI BOGDANOV, VLADIMIR · 2015 to 2019
$1.4M
NCI NIH HHS R01 CA190717NCI NIH HHS T32 CA236764NIDDK NIH HHS P30 DK078392
6 · The paper itself

Abstract

In 2021, pancreatic ductal adenocarcinoma (PDAC) is the 3

Indexed as

alternative splicingmonoclonal antibodiesorthotopic tumor modelpancreatic ductal adenocarcinomatissue factor

Identifiers

PMID34395257
PMCPMC8358774
OpenAlexW3190984096

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.